GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by Aptus Capital Advisors LLC

Aptus Capital Advisors LLC grew its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 17.4% during the third quarter, Holdings Channel reports. The firm owned 4,205 shares of the company’s stock after acquiring an additional 622 shares during the quarter. Aptus Capital Advisors LLC’s holdings in GE HealthCare Technologies were worth $395,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of GEHC. Russell Investments Group Ltd. increased its holdings in shares of GE HealthCare Technologies by 11.3% in the 1st quarter. Russell Investments Group Ltd. now owns 89,220 shares of the company’s stock worth $8,110,000 after acquiring an additional 9,045 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of GE HealthCare Technologies by 171.0% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 33,780 shares of the company’s stock worth $3,071,000 after acquiring an additional 21,316 shares during the period. Blair William & Co. IL increased its holdings in shares of GE HealthCare Technologies by 11.0% in the 1st quarter. Blair William & Co. IL now owns 109,964 shares of the company’s stock worth $9,997,000 after acquiring an additional 10,928 shares during the period. Orion Portfolio Solutions LLC increased its holdings in shares of GE HealthCare Technologies by 79.5% in the 1st quarter. Orion Portfolio Solutions LLC now owns 40,584 shares of the company’s stock worth $3,690,000 after acquiring an additional 17,970 shares during the period. Finally, Dorsey & Whitney Trust CO LLC increased its holdings in shares of GE HealthCare Technologies by 14.2% in the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 6,722 shares of the company’s stock worth $611,000 after acquiring an additional 837 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. UBS Group cut shares of GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $84.00 to $74.00 in a research note on Thursday, September 26th. Redburn Atlantic raised shares of GE HealthCare Technologies to a “strong-buy” rating in a research note on Thursday, August 1st. Evercore ISI raised their target price on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a research note on Monday, September 9th. They set a “neutral” rating and a $90.00 target price on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies presently has an average rating of “Moderate Buy” and an average target price of $94.36.

Insiders Place Their Bets

In related news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the transaction, the chief executive officer now directly owns 24,298 shares of the company’s stock, valued at $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Trading Down 1.4 %

Shares of GE HealthCare Technologies stock opened at $81.76 on Friday. GE HealthCare Technologies Inc. has a 1 year low of $66.39 and a 1 year high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. The company’s fifty day simple moving average is $88.70 and its 200-day simple moving average is $83.43. The company has a market cap of $37.35 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 3.02 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. During the same quarter in the previous year, the company earned $0.99 earnings per share. The business’s revenue was up .9% compared to the same quarter last year. As a group, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.29 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Friday, October 18th were paid a dividend of $0.03 per share. The ex-dividend date of this dividend was Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a yield of 0.15%. GE HealthCare Technologies’s dividend payout ratio is currently 3.30%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.